| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $8.0M | -11.7% | -26.0% |
| SG&A Expense | $3.2M | -23.3% | -45.0% |
| Operating Income | -$11.5M | +14.9% | +35.2% |
| Pre-tax Income | -$11.1M | +16.3% | +35.3% |
| Net Income | -$11.1M | +16.3% | +35.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $3.2M | -19.1% | -55.2% |
| Short-term Investments | $10.3M | -48.9% | -80.9% |
| Current Assets | $15.1M | -42.2% | -76.4% |
| Total Assets | $29.3M | -28.2% | -63.6% |
| Current Liabilities | $3.2M | -37.7% | -63.1% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$35.8M | — | — |
| Investing Cash Flow | $29.1M | — | — |
| Financing Cash Flow | $67K | — | — |
| $15.3M |
| -14.4% |
| -32.9% |
| Stockholders' Equity | $14.1M | -38.9% | -75.7% |